Dalit Engelhardt

Dalit Engelhardt

Auto-generated profile, based on publicly available information

Dalit Engelhardt

Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Cell Reports
Verified
Journal Article
Open access
KWKacper A. Walentynowicz
Kacper A. Walentynowicz
DEDalit Engelhardt
Dalit Engelhardt
SCSimona Cristea
Simona Cristea
SYShreya Yadav
Shreya Yadav
UOUgoma Onubogu
Ugoma Onubogu
MJMichalina Janiszewska
Michalina Janiszewska
Glioblastoma (GBM) is the most aggressive brain tumor, with a median survival of ~15 months. Targeted approaches have not been successful in this tumor type due to the large extent of intratumor heterogeneity. Mosaic amplification of oncogenes suggests that multiple genetically distinct clones are present in each tumor. To uncover the relationships between genetically diverse subpopulations of GBM cells and their native tumor microenvironment, we employ highly multiplexed spatial protein profiling coupled with single-cell spatial mapping of fluorescence in situ hybridization (FISH) for EGFR, CDK4, and PDGFRA. Single-cell FISH analysis of a total of 35,843 single nuclei reveals that tumors in which amplifications of EGFR and CDK4 more frequently co-occur in the same cell exhibit higher infiltration of CD163+ immunosuppressive macrophages. Our results suggest that high-throughput assessment of genomic alterations at the single-cell level could provide a measure for predicting the immune state of GBM.

1 April 2021 in Trends in Cancer
Verified
Journal Article
Closed access
DEDalit Engelhardt
Dalit Engelhardt
FMFranziska Michor
Franziska Michor

16 October 2020 in arXiv
Verified
Preprint
Open access
PDF file
DEDalit Engelhardt
Dalit Engelhardt
The challenge in controlling stochastic systems in which low-probability events can set the system on catastrophic trajectories is to develop a robust ability to respond to such events without significantly compromising the optimality of the baseline control policy. This paper presents CelluDose, a stochastic simulation-trained deep reinforcement learning adaptive feedback control prototype for automated precision drug dosing targeting stochastic and heterogeneous cell proliferation. Drug resistance can emerge from random and variable mutations in targeted cell populations; in the absence of an appropriate dosing policy, emergent resistant subpopulations can proliferate and lead to treatment failure. Dynamic feedback dosage control holds promise in combatting this phenomenon, but the application of traditional control approaches to such systems is fraught with challenges due to the complexity of cell dynamics, uncertainty in model parameters, and the need in medical applications for a robust controller that can be trusted to properly handle unexpected outcomes. Here, training on a sample biological scenario identified single-drug and combination therapy policies that exhibit a 100% success rate at suppressing cell proliferation and responding to diverse system perturbations while establishing low-dose no-event baselines. These policies were found to be highly robust to variations in a key model parameter subject to significant uncertainty and unpredictable dynamical changes.

30 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DEDalit Engelhardt
Dalit Engelhardt
TMThomas O. McDonald
Thomas O. McDonald
The simulation of clonal dynamics with branching processes can provide valuable insights into disease progression and treatment optimization, but exact simulation of branching processes via the Stochastic Simulation Algorithm (SSA) is computationally prohibitive at the large population sizes associated with therapeutically-relevant scenarios. evosim is a versatile and flexible Python implementation of a fast and unbiased tau-leaping algorithm for the simulation of birth-death-mutation branching processes that is scalable to any population size. Package functionalities support the incorporation and tracking of a sequence of evolutionary changes such as therapeutic interventions as well as the analysis of population diversity. We show that runtimes scale logarithmically with population size, by contrast to the linear scaling of the SSA, and simulations exhibit strong agreement with SSA simulation results. These findings are also supported by mathematical results (Supplementary information). Availability: Package, documentation, and tutorials / usage examples are available on GitHub ( https://github.com/daliten/evosim ). Mathematical details of the algorithm and the pseudocode are provided in the included Supplementary information.